Current Report Filing (8-k)
19 December 2017 - 8:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 14, 2017
CHINA
PHARMA HOLDINGS, INC.
(Exact
name of Registrant as specified in charter)
Nevada
|
|
001-34471
|
|
73-1564807
|
(State
or other jurisdiction
|
|
(Commission
File No.)
|
|
(IRS
Employer
|
of
Incorporation)
|
|
|
|
Identification
No.)
|
Second
Floor, No. 17, Jinpan Road
Haikou,
Hainan Province, China 570216
(Address
of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code:
+86 898-6681-1730 (China)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
☐
Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
5.07
|
Submission
of Matters to a Vote of Security Holders.
|
On
December 14, 2017, China Pharma Holdings, Inc. (the “Company”) held its annual shareholders meeting for the fiscal
year ended December 31, 2016 (the “Annual Meeting”). Holders of 25,450,180 shares of the Company’s common stock
were present in person or by proxy at the Annual Meeting, representing 58.4% of the total outstanding shares of common stock and
therefore constituting a quorum of more than one-third of the shares outstanding and entitled to vote at the Annual Meeting as
of the record date.
The
final voting results for the matter submitted to a vote of shareholders at the meeting are as follows. No broker non-votes were
counted for the proposal.
A
proposal to elect three independent director nominees to our Board of Directors to serve until the next annual meeting and until
their successors are elected and qualified:
Director’s Name
|
|
Votes For
|
|
|
Votes Withheld
|
|
Gene Michael Bennett
|
|
|
23,802,030
|
|
|
|
1,648,150
|
|
Yingwen Zhang
|
|
|
23,802,178
|
|
|
|
1,648,002
|
|
Baowen Dong
|
|
|
23,801,129
|
|
|
|
1,649,051
|
|
Pursuant
to the foregoing votes, Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as independent directors.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
December 18, 2017
|
CHINA PHARMA HOLDINGS, INC.
|
|
|
|
|
By:
|
/s/ Zhilin Li
|
|
Name:
|
Zhilin Li
|
|
Title:
|
President and Chief Executive Officer
|
2
China Pharma (AMEX:CPHI)
Historical Stock Chart
From Apr 2024 to May 2024
China Pharma (AMEX:CPHI)
Historical Stock Chart
From May 2023 to May 2024